Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Molecular Partners AGMLLCF 34 Cash-to-Debt is 23.56 as of Mar. 2026, which is 55% below its 10-year median of 51.93. GuruFocus rates MLLCF with a GF Score™ of 34/100. The stock has 3 warning signs investors should review. Among 1,400 Biotechnology companies, Molecular Partners AG ranks better than 64.29% on this metric.
Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Molecular Partners AG's cash to debt ratio for the quarter that ended in Mar. 2026 was 23.56.
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Molecular Partners AGcould pay off its debt using the cash in hand for the quarter that ended in Mar. 2026.
The historical rank and industry rank for Molecular Partners AG's Cash-to-Debt or its related term are showing as below:
MLLCF'
s Cash-to-Debt Range Over the Past 10 Years
Min: 21.99 Med: 51.93 Max: No Debt
Current: 23.56
During the past 13 years, Molecular Partners AG's highest Cash to Debt Ratio was No Debt. The lowest was 21.99. And the median was 51.93.
MLLCF's Cash-to-Debt is ranked better than 64.29% of 1400
companies
in the Biotechnology industry
Industry Median: 6.21
vs MLLCF: 23.56
Molecular Partners AG (OTCPK:MLLCF) Cash-to-Debt Explanation
If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.
Molecular Partners AG Cash-to-Debt Related Terms
Molecular Partners AG Cash-to-Debt Historical Data
* Premium members only.
The historical data trend for Molecular Partners AG's Cash-to-Debt can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
MLLCF vs VRTX, REGN, RVMD: Cash-to-Debt Comparison
For the Biotechnology subindustry, Molecular Partners AG's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Molecular Partners AG Cash-to-Debt vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Molecular Partners AG's Cash-to-Debt distribution charts can be found below:
* The bar in red indicates where Molecular Partners AG's Cash-to-Debt falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Molecular Partners AG (MLLCF) has a Cash-to-Debt of 23.56 as of Mar. 2026. This is 55% below median its historical median of 51.93. Over the past decade, Molecular Partners AG's Cash-to-Debt has ranged from 21.99 to 10,000.00. According to the industry distribution chart, Molecular Partners AG ranks #500 out of 1400 companies in the Biotechnology industry, placing it in the top 35.7%.
Is Molecular Partners AG's Cash-to-Debt too high?
Molecular Partners AG's current Cash-to-Debt of 23.56 is 55% below median its 10-year median of 51.93. Over the past 10 years, this metric has ranged from a low of 21.99 to a high of 10,000.00. The Biotechnology industry median Cash-to-Debt is 6.21. Molecular Partners AG's value of 23.56 is 279.4% above this industry median. Based on the distribution chart, Molecular Partners AG ranks #500 out of 1400 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Molecular Partners AG has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Molecular Partners AG's Cash-to-Debt compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Molecular Partners AG ranks #500 out of 1400 companies for Cash-to-Debt. This puts Molecular Partners AG in the upper half of its industry. The industry median Cash-to-Debt is 6.21. Molecular Partners AG's value of 23.56 is 279.4% above this benchmark. Historically, Molecular Partners AG's own Cash-to-Debt has ranged from 21.99 to 10,000.00 over the past decade. While the company's 10-year median is 51.93 vs. the industry median of 6.21, Molecular Partners AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash-to-Debt for a Biotechnology company?
The median Cash-to-Debt among Biotechnology companies is 6.21, based on 1,400 companies in the industry. Companies in the top quartile (top 25%) have a Cash-to-Debt significantly above this median, while those in the bottom quartile fall well below. However, Cash-to-Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Molecular Partners AG's current Cash-to-Debt of 23.56 is 279.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash-to-Debt mean?
A high Cash-to-Debt can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Cash-to-Debt is 6.21 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Molecular Partners AG's current Cash-to-Debt is 23.56, which is 55% below median its own 10-year median of 51.93. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Molecular Partners AG stock overvalued right now?
Molecular Partners AG (MLLCF) has a current Cash-to-Debt of 23.56. The current Cash-to-Debt is 23.56, which is 55% below median its 10-year median of 51.93 and 279.4% above the Biotechnology industry median of 6.21. Molecular Partners AG's overall GF Score™ is 34/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash-to-Debt calculated?
Cash-to-Debt is calculated from a company's financial statements. For Molecular Partners AG (MLLCF), the current Cash-to-Debt is 23.56 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
34GF Score
Get the complete analysis for MLLCF
Cash-to-Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MLLCF has been successfully added to your 
